Novo Nordisk participates in USD 57m financing round at strategic partner

Beta Bionics, a partner of both Novo Nordisk and Zealand Pharma, has closed a USD 57m series C financing round with participation from existing investors, including Novo Nordisk, and one newcomer.

Photo: Tidsvilde Stine/Ritzau Scanpix

A partner of Danish pharmaceutical firm Novo Nordisk, US-based Beta Bionics, has been on a successful capital hunt, bringing in USD 57m in a series C financing round, the company informs in a press release.

Existing investors, including Novo Nordisk, participated in the capital raise, with one new investor joining the scene.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs